Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 10/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CPB1 | P15086 | 2/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031885 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CCR2CYP2D6CYP3A4KCNH2 | |
| SCHEMBL5029290 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CCR2CYP2D6CYP3A4KCNH2 | |
| SCHEMBL5029280 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CCR2CYP2D6CYP3A4KCNH2 | |
| SCHEMBL5029146 | 0.82 | CPB1 (0.45) | ALDH1A1CCR2CYP2D6CYP3A4KCNH2 | |
| SCHEMBL5030515 | 0.80 | CPB1 (0.50) | ALDH1A1CYP3A4CPB1 | |
| SCHEMBL5030509 | 0.80 | CPB1 (0.50) | ALDH1A1CYP3A4CPB1 | |
| SCHEMBL5029501 | 0.76 | CPB1 (0.46) | ALDH1A1CPB1KDM1ARCOR1 | |
| SCHEMBL5029500 | 0.76 | CPB1 (0.46) | ALDH1A1CPB1KDM1ARCOR1 | |
| SCHEMBL5029129 | 0.75 | CPB1 (0.43) | ALDH1A1CPB1 | |
| SCHEMBL5029137 | 0.75 | CPB1 (0.43) | ALDH1A1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | ALDH1A1 827/4885CCR2 3/4885CYP2D6 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.